Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 537,802
  • Shares Outstanding, K 58,712
  • Annual Sales, $ 106,470 K
  • Annual Income, $ 83,230 K
  • EBIT $ 0 M
  • EBITDA $ 59 M
  • 60-Month Beta 0.91
  • Price/Sales 5.18
  • Price/Cash Flow 9.94
  • Price/Book 3.42

Options Overview Details

View History
  • Implied Volatility 133.23% (-136.82%)
  • Historical Volatility 66.54%
  • IV Percentile 66%
  • IV Rank 28.50%
  • IV High 339.85% on 03/03/26
  • IV Low 50.87% on 05/22/25
  • Expected Move (DTE 17) 0.92 (10.46%)
  • Put/Call Vol Ratio 0.70
  • Today's Volume 138
  • Volume Avg (30-Day) 1,780
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 46,723
  • Open Int (30-Day) 47,698
  • Expected Range 7.86 to 9.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.06
  • Number of Estimates 3
  • High Estimate 0.12
  • Low Estimate 0.01
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.42 +4.28%
on 03/06/26
11.40 -22.98%
on 03/10/26
-0.15 (-1.68%)
since 02/27/26
3-Month
8.08 +8.66%
on 01/12/26
11.40 -22.98%
on 03/10/26
-0.09 (-1.01%)
since 12/26/25
52-Week
6.19 +41.84%
on 04/09/25
13.16 -33.28%
on 07/15/25
+0.93 (+11.85%)
since 03/28/25

Most Recent Stories

More News
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 8.78 (-4.15%)
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 8.78 (-4.15%)
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

ZVRA : 8.78 (-4.15%)
WGS : 59.61 (+4.41%)
Zevra Therapeutics: Q4 Earnings Snapshot

Zevra Therapeutics: Q4 Earnings Snapshot

ZVRA : 8.78 (-4.15%)
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million , driven by growth in MIPLYFFA ® net revenue to $87.4 million...

ZVRA : 8.78 (-4.15%)
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.78 (-4.15%)
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.78 (-4.15%)
Zevra Therapeutics to Present at the Citizens Life Sciences Conference

CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.78 (-4.15%)
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor...

ZVRA : 8.78 (-4.15%)
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.78 (-4.15%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 9.49
2nd Resistance Point 9.32
1st Resistance Point 9.05
Last Price 8.78
1st Support Level 8.61
2nd Support Level 8.44
3rd Support Level 8.17

See More

52-Week High 13.16
Fibonacci 61.8% 10.50
Fibonacci 50% 9.68
Fibonacci 38.2% 8.85
Last Price 8.78
52-Week Low 6.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.